Carlyle, PEP to buy iNova Pharma from Valeant for $930m

Carlyle, PEP to buy iNova Pharma from Valeant for $930m

A sign for the headquarters of Valeant Pharmaceuticals International Inc is seen in Laval, Quebec June 14, 2016. REUTERS/Christinne Muschi

09 June, 2017

Baker & McKenzie Bausch & Lomb Carlyle Group LP dendreon Goldman Sachs & Co iNova Pharmaceuticals Joseph Papa Mike Pearson Pacific Equity Partners Salix Takeda Pharmaceutical Co Ltd Valeant Pharmaceuticals International Inc

Printed by Unregistered user on Wed, 15 Apr 2026 20:32:33 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

Read more from World

No signs of major default cycle in private credit: Ares CEO

Earnings and Results

BlackRock posts Q1 profit rise on active ETFs, performance fees